期刊文献+

吡非尼酮片在中国健康人体的药动学研究 被引量:1

Study on Pharmacokinetics of Pirfenidone Tablets in Chinese Healthy Volunteers
下载PDF
导出
摘要 目的:研究吡非尼酮片在中国健康人体的药动学特征。方法:采用Inspire-C_(18)(150 mm×4.6 min,5μm,Dikma)分析柱,甲醇-水含0.2%的磷酸(59:41)为流动相,检测波长为310 nm,流速为1 ml·min^(-1);血浆样品经10%高氯酸溶液沉淀蛋白后直接进样。30名健康受试者随机分为低、中、高3个剂量组,每组10人(男女各半),分别单次口服吡非尼酮片200,400,600 mg,采用HPLC测定血浆中吡非尼酮的浓度并采用WinNonLin 6.2计算药动学参数。结果:人血浆中吡非尼酮的最低定量限为0.2μg·ml^(-1),在0.2~25μg·ml^(-1)范围内线性关系良好,批内及批间精密度RSD均小于15%。主要药动学参数:C_(max)分别为(6.08±6.08)、(11.97±1.34)和(15.71±1.74)μg·ml^(-1);t_(max)分别为(0.63±0.13)、(0.63±0.23)和(0.58±0.19)h;t_(1/2)分别为(2.02±0.47)、(2.15±0.50)和(2.59±0.56)h;AUC_(0-t)分别为(14.79±3.04)、(29.54±8.50)和(47.02±5.85)μg·h·ml^(-1);AUC_(0-∞)分别为(15.77±3.21)、(30.67±9.15)和(50.06±6.07)μg·h·ml^(-1)。结论:3个剂量组(200~600 mg)中吡非尼酮在人体内的AUC_(0-t),AUC_(0-∞)和C_(max)均与剂量呈线性关系。 Objective:To study the pharmacokinetics of pirfenidone tablets in Chinese healthy volunteers.Method:The plasma samples were analyzed on an Inspire-C_(18)(150 mm×4.6 mm,5μm,Dikma) column with methanol-water(0.2%phosphoric acid) (59:41) as the mobile phase.The flow rate was 1 ml ? min^(-1) and the detection wavelength was 310 nm.The samples were denatured by 10%perchloric acid.Thirty healthy volunteers were randomly divided into three groups with 10 volunteers in each group(5 males and 5 females).The three groups received pirfenidone tablets with a single dose of 200,400 and 600 mg,respectively.The concentrations of pirfenidone in human plasma at different times were determined by HPLC and the pharmacokinetic parameters were calculated by WinNonLin 6.2 software.Result:The limit of quantitation(LOQ) of pirfenidone was 0.2μg ? ml^(-1).The calibration curve was linear over the range of 0.2-25μg ? ml^(-1).The intra- and inter-day RSDs were less than 15%.The pharmacokinetic parameters were as follows;C_(max) of(6.08±6.08),(11.97±1.34)and(15.71±1.74)μg ? ml^(-1),t_(max) of(0.63±0.13),(0.63±0.23)and(0.58±0.19)h,t_(1/2)of(2.02±0.47),(2.15±0.50) and(2.59±0.56)h,AUC_(0-t) of(14.79±3.04),(29.54±8.50)and(47.02±5.85)μg·h·ml^(-1),and AUC_(0-∞) of(15.77±3.21),(30.67±9.15) and(50.06±6.07)μg ? h ? ml^(-1).Conclusion:The values of AUC_(0-t),AUC_(0-∞) and C_(max) are linear within the dose range of 200-600 mg.
出处 《中国药师》 CAS 2013年第1期40-43,共4页 China Pharmacist
关键词 吡非尼酮 药动学 高效液相色谱法 Pirfenidone Pharmacokinetics HPLC
  • 相关文献

参考文献7

  • 1Shi S,Wu J,Chen H. Single-and multiple-dose pharmacokinetics of pirfenidone,an antifibrotic agent,in healthy Chinese volunteers[J].Journal of Clinical Pharmacology,2007,(10):1268-1276.
  • 2Azuma A,Taguchi Y,Ogura T. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment[J].BioMed Central Volume,2011,(01):143-153.
  • 3Noble PW,Albera C,Bradford WZ. Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY):two randomized trials[J].Lancet,2011,(9779):1760-1769.
  • 4Taniyama M,Ohbayashi S,Narita M. Pharmacokinetics of an antifibrotic agent,pirfenidone,in haemodialysis patients[J].European Journal of Clinical Pharmacology,1997,(01):77-78.
  • 5Rubino CM,Bhavnani SM,Ambrose PG. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults[J].Pulmonary Pharmacology and Therapeutics,2009.279-285.
  • 6师少军,吴健鸿,陈汇,陈华庭,曾繁典.高效液相色谱法测定人血浆吡非尼酮浓度[J].中国药学杂志,2011,46(2):138-141. 被引量:6
  • 7王永升,赵小平,钟皎,陈燕,柳晓泉,王广基.HPLC-UV法测定比格犬血浆中吡非尼酮浓度及其药代动力学[J].中国药科大学学报,2006,37(2):146-149. 被引量:8

二级参考文献14

  • 1NICOD L P. Pirfenidone in idiopathic pulmonary fibrosis [ J]. Lancet, 1999,354(9175) :268-269.
  • 2GARC A L, HERN NDEZ I, SANDOVAL A, et al. Pirfenidone effectively reverses experimental liver fibrosis [ J ] . J Hepatol, 2002,37 ( 6 ) : 797-805.
  • 3MIRIC G, DALLEMAGNE C, ENDRE Z, et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats[ J]. Br J Pharmacol, 2001 , 133 (5) :687- 694.
  • 4AL-BAYATI M A, XIE Y, MOHR F C, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats [J].Biochem Pharmacol, 2002,64 ( 3 ) :517-525.
  • 5TANIYAMA M, OHBAYASHI S, NARITA M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients[J]. Eur J Clin Pharmacol, 1997,52( 1 ) :77-78.
  • 6GIRI S N, WANG Q, XIE Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration [ J ]. Biopharm Drug Dispos, 2002,23 (5) :203-211.
  • 7TANIYAMA M, OHBAYASHI S, NARITA M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients [ J]. Eur J Clin Pharmacol, 1997,52 ( 1 ) :77-78.
  • 8Iyer SN,Wild JS,Schiedt MJ,et al.Dietary intake of pirfenidone ameliorates blemycin-induced lung fibrosis in hamsters[J].J Lab Clin Med,1995,125(6):779-785.
  • 9Iyer SN,Margolin SB,Hyde DM,et al.Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model[J].Exp Lung Res,1998,24(1):119-132.
  • 10Dosanjh A,Wan B,Throndset S,et al.Pirfenidone:a novel antifibrosis agent with implications for the treatment of obliterative bronchiolitis[J].Transplant Proc,1998,30(5):1 910-1 911.

共引文献10

同被引文献8

  • 1Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [ J]. Cancer Res, 2008 ;68:4774-4782.
  • 2Antoniu SA, Kolb MR. Nintedanib, a triple kinase inhibitor of VEG- FR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis[ J ]. IDrugs ,2010 ; 13:332-345.
  • 3Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-in- flammatory activity of the tyrosine kinaaeinhibitor nintedanib in exper- imental models of lung fibrosis[ J ]. J Phartru~l Exp Ther, 2014; 349:209-20.
  • 4Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nint- odanib in idiopathic pulmonary fibrosis[J]. N Engl J Med,2014; 370 : 2071-2082.
  • 5Tai WT,Shian CW,Li YS, ,et al. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity [J]. Journal of Hepatology , 2014 ; 61: 8 9-9 7.
  • 6Novello S,Kaiser R, Mellemgaard A, eta/. Analysis of patient-repor- ted outcomes from the LUME Lung 1 trial: A randomised, double- blind, placebo controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer [ J ]. European Journal of Cancer,2015 ; 51:317-326.
  • 7Capdevila J, Carrato A, Tabernero J, et al. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options forpatients with metastatic color- ectal cancer? [ J ]. Critical Reviews in Oncology/Hemataloffy,2014 ; 92:83-106.
  • 8马忠英,鹿成韬,宋薇,周伦,葛洁,李健康,李帆,丁莉坤,文爱东.LC-MS/MS法测定人血浆中尼莫地平浓度及其药动学研究[J].中国药师,2015,18(10):1689-1692. 被引量:2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部